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Abstract Mitochondrial disease is one of the most
common groups of genetic diseases with a minimum
prevalence of greater than 1 in 5000 in adults. Whilst
multi-system involvement is often evident, neurological
manifestation is the principal presentation in most cases.
The multiple clinical phenotypes and the involvement of
both the mitochondrial and nuclear genome make mito-
chondrial disease particularly challenging for the clinician.
In this review article we cover mitochondrial genetics and
common neurological presentations associated with adult
mitochondrial disease. In addition, specific and supportive
treatments are discussed.
Keywords Mitochondrial disease  Mitochondrial DNA
(mtDNA)  Nuclear genes  Acute and chronic neurological
presentations  Treatment
Introduction
Mitochondrial disease is a collective term that encom-
passes the genetically and clinically heterogeneous group
of diseases due to defects in mitochondrial oxidative
phosphorylation. It is one of the most common groups of
genetic disease and can be caused by mutation in either
mitochondrial DNA or nuclear genes that directly or indi-
rectly interfere with the mitochondrial respiratory chain
function. To date, mitochondrial proteomics analysis
reveals that in addition to the 13 proteins encoded by the
mitochondrial genome, around 1500 proteins [50] are
linked to various mitochondrial functions and so far more
than 200 genes have been implicated in the development of
human disease [40].
A number of syndromes have been described in mito-
chondrial disease but often patients present with non-syn-
dromic presentation of which nervous system is most
commonly affected [49]. In addition to the diagnostic
challenge, clinicians also encounter difficulty in the man-
agement of mitochondrial disease due to lacking of effec-
tive disease-modifying therapy and, until recently, best
practice guidelines on various complications associated
with the disease [59].
In this review article, we discuss the genetics and epi-
demiology of mitochondrial disease, neurological presen-
tations and their management, genetic counselling and
reproductive options for patients.
Mitochondrial genetics
Mitochondria are cellular organelles found in all nucleated
human cells. A crucial function of mitochondria is to
generate energy in the form of ATP (adenosine triphos-
phate) via oxidative phosphorylation using predominantly
carbohydrates and fatty acids as fuel. The oxidative phos-
phorylation system (OXPHOS) is located in the inner
membrane and it consists of five multimeric protein com-
plexes: complex I-IV form the respiratory chain and com-
plex V (ATP synthase). In addition, there are two mobile
electron carriers (co-enzyme Q10 and cytochrome c).
Mitochondria are under dual genetic control of the
mitochondrial and nuclear genomes. The mitochondrial
genome consists of multiple copies of 16,569 bp, double
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stranded mitochondrial DNA (mtDNA) molecules and
located adjacent to the OXPHOS system in the matrix.
Only thirty-seven genes (22 transfer RNAs, 2 ribosomal
RNAs and 13 polypeptides that form structural subunits of
OXPHOS system) [86] are encoded by mtDNA. The
remaining mitochondrial proteins, including the majority of
respiratory chain subunits (79 out of 92), assembly factors
of the respiratory chain, those involved in maintenance and
expression of mtDNA, mtDNA transcription and transla-
tion, and control the mitochondrial dynamics are nuclear
encoded [16], synthesised in the cytosol and imported to
the mitochondria [51].
There are several unique properties associated with the
mitochondrial genome that are important in understanding
the primary mitochondrial DNA disease: (1) there are
multiple copies (up to thousands) of mtDNA in each cell;
(2) mtDNA is maternally inherited; (3) the phenomenon of
homoplasmy and heteroplasmy. Homoplasmy implies all
mtDNA are identical which could be all wild type or
mutated. Heteroplasmy is a mixture of mutated and wild
type mtDNA. In the presence of heteroplasmy there is a
threshold effect and clinical expression can vary between
different tissues and mtDNA mutations. In women with
heteroplasmic mtDNA mutations there is a bottleneck in
the female germline which means that the transmission of
heteroplasmy level from mother to offspring is often ran-
dom and unpredictable. This explains the heterogeneity in
heteroplasmy level, clinical phenotype and severity fre-
quently observed within the same pedigree.
Multiple mtDNA deletions and mtDNA depletion (re-
duced copy number of mtDNA) are secondary changes in
mtDNA due to mutations in the mtDNA replication and/or
maintenance genes such as POLG, PEO1, ANT1, DGUOK,
TYMP [72]. Mitochondrial depletion syndrome is associ-
ated with infantile/early childhood onset, multi-system
disease with fatal outcome and multiple deletions generally
result in later onset (child- or adulthood) and milder disease
burden.
The emergence of next generation sequencing is lead-
ing to rapid discovery of new nuclear genes linked to
mitochondrial disease and the classification of nuclear
gene related mitochondrial disease is summarised in
Table 1. There is also increased recognition of mito-
chondrial dysfunction and genetic mutation in various
other genetic neurological disorders, for examples SPG7
gene in hereditary spastic paraplegia [58] and ataxia [61]
and GDAP1 gene in Charcot-Marie-Tooth disease type 4A
[56, 96].
The inheritance pattern of mitochondrial disease is
dependent on the genetic mutations. Point mutations in the
primary mitochondrial DNA such as m.3243A[G, three
common LHON mutations, m.8344A[G, m.8993T[G/C,
m.1555A[G and others are maternally inherited but
sporadic mutations exist [53]. Single, large deletions in
mtDNA are a common cause mitochondrial disease and
they occur sporadically with rare exceptions [15]. The
inheritance patterns of mutations in nuclear genes causing
mitochondrial disease include autosomal recessive, domi-
nant or X-linked. Both recessive and dominant forms exist
in several mtDNA maintenance genes, for examples
POLG, PEO1 and RRM2B genes.
Epidemiology of mitochondrial disease
The overall prevalence of mitochondrial disease is com-
parable to other neurogenetic diseases such as Charcot-
Marie-Tooth (CMT) disease, myotonic dystrophy and
muscular dystrophy. The prevalence of adult mitochondrial
disease, both affected patients and those at risk, has
recently been reported to be approximately 1 in 4300 in
North East England [28]. Primary mutations in the mtDNA
are more prevalent in the adult patients compared to
mutations in the nuclear genes, and vice versa in the pae-
diatric population where there is a much higher incidence
of autosomal recessive disease particularly in consan-
guineous families. Although several hundreds of mutations
have been reported in mtDNA since 1988, a handful of
mutations are far more common than the others, for
examples m.1555A[G (associated with aminoglycoside
induced deafness), m.3243A[G (associated with MELAS
syndrome and MIDD), m.3460G[A and m.11778A[G
(associated with LHON), have an estimated prevalence of
0.19, 0.14, 0.11 and 0.11 %, respectively, in the population
[11, 21]. However, individuals with these common muta-
tions may remain clinically asymptomatic throughout their
life if not exposed to relevant toxin or if they have a low
mutation load.
Clinical diagnosis
Mitochondria are ubiquitous and therefore mitochondrial
disease can affect any organ, although organs with high
energy demand such as brain, skeletal muscle and heart, are
more commonly affected than the others. The clinical
features are heterogeneous and often can mimic many
neurological or other systemic diseases. Multi-system
involvement is often evident with detailed clinical exami-
nation and investigations in most cases although there are
exceptions such as Leber hereditary optic neuropathy
(LHON). Paediatric onset disease is associated with more
severe multi-systemic involvement, relentless progression
and poorer prognosis, however, there are rare exceptions
such as reversible respiratory chain deficiency caused by
the m.14674T[C mutation [33].
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Many classic syndromes have been described over the
last few decades. The examples of clinical syndromes
associated with adolescence and adulthood include mito-
chondrial encephalomyopathy, lactic acidosis with stroke-
like episode (MELAS), myoclonic epilepsy with ragged
red fibres (MERRF), mitochondrial neuro-gastrointestinal
involvement and encephalopathy (MNGIE), neuropathy,
ataxia and retinitis pigmentosa (NARP), chronic progres-
sive external ophthalmoplegia (CPEO). In contrast, syn-
dromes with neonatal and childhood onset include Alpers
disease, Pearson syndrome, Leigh disease, Sengers syn-
drome and Kearns-Sayre syndrome.
However, clinicians are more commonly confronted by
the non-specific constellation of clinical features. Many
symptoms associated with mitochondrial disease such as
deafness, diabetes, myopathy, gastrointestinal symptoms
and others are also common on their own in the population
but the ‘unusual’ combination of these symptoms in the
same individual should alert the clinicians about the pos-
sibility of mitochondrial disease. Detailed system-based
examination coupled with extended investigations is nec-
essary to identify other system involvement such as short
stature, sensori-neural deafness, pigmentary retinopathy,
optic atrophy, diabetes mellitus and/or other endocrine
dysfunction, cardiac involvement, renal tubulopathy and
others. This systemic involvement may be subtle and
asymptomatic in the early phase of disease. Disease rating
scales have been utilised to document the extent of system
involvement, disease burden and progression in paediatric
and adult patients [62, 69].
Family history can be informative and often reveals
what appear to be seemingly unrelated diseases among the
maternal family members in primary mtDNA disease and
the m.3243A[G mutation is a prime example [54]. It is
important to ascertain history of consanguinity when
recessive disease is suspected. Late adulthood presentation
and/or lacking of apparent family history should not deter
testing for mitochondrial disease because sporadic muta-
tions or late presenting autosomal dominant diseases are
not uncommon.
Acute neurological presentations
Stroke-like episodes and acute symptomatic seizure
MELAS syndrome is a severe, multi-system disease char-
acterised by recurrent metabolic strokes with typical onset
of below 40 years [31] although patients at the older age
have been reported [6, 92]. Headache and prominent visual
disturbance (both positive and negative symptoms) are
often the prodrome of acute stroke-like episodes and can
occur days or weeks before the development of focalT
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neurological deficit or motor seizure. These visual symp-
toms can masquerade as migranous visual aura but in fact
is the onset of occipital seizure [24, 35]. The severity of
neurological deficits are related to the extent of parietal,
temporal and occipital lobe involvement such as dysphasia,
dyspraxia, heminanopia, cortical blindness, mild hemi-
paresis and psychosis. Epilepsia partialis continua and less
commonly generalised status epilepticus occur during the
stroke-like episodes in some patients.
The key imaging findings are cortical and subcortical
lesions that cross the vascular territories of middle cerebral
artery and posterior cerebral arteries and bilateral, asym-
metrical changes are not infrequent (Fig. 1). The most
common cause of MELAS phenotype is m.3243A[G
mutation which accounts for 80 % of cases but mutations
in the nuclear gene POLG, encoding for the catalytic
subunit of DNA polymerase c (pol c), can cause similar
stroke-like lesions [14, 19]. However, the POLG-related
disease often has more aggressive disease course with
explosive onset of focal seizure and status epilepticus that
is highly refractory to pharmacological treatments in chil-
dren and young adults and the outcome is very poor.
Administration of sodium valproate is recognised to trigger
fulminant hepatic failure among patients with POLG dis-
ease [73, 80]. In contrast, patients who have stroke-like
episodes associated with the m.3243A[G mutation tend to
have pre-existing, and often subtle, multi-system involve-
ment and they often make good recovery in conjunction
with the partial or complete resolution of imaging changes
within few weeks or months at the early course of disease if
appropriately managed (refer to Treatment section). Nev-
ertheless, recurrence of stroke-like episodes leads to
cumulative neuronal loss and results in severe cognitive
impairment.
Given the high prevalence of m.3243A[G mutation and
common carrier status of several pathogenic variants in
POLG gene (p. A467T, p. W748S and p. G848S) in pop-
ulations of European descent [29], clinicians should pri-
oritise mitochondrial disease as a main differential
diagnosis to atypical, evolving posterior circulation stroke,
recurrent ‘encephalitis/encephalopathy’ with negative
infective screen, auto-antibodies and ‘atypical/recurrent’
posterior reversible encephalopathy syndrome (PRES).
Securing the diagnosis of mitochondrial disease early can
Fig. 1 Axial FLAIR (a, b) and
DWI (c, d) sequences of MRI
head. a and c were performed
on admission whilst b and
d were performed 8 days later.
The stroke-like lesion ‘spread’
from the right occipital lobe to
the right temporal lobe and
thalamus
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avert the patients having invasive diagnostic procedure
such as brain biopsy or potentially harmful treatment such
as immune-suppressants.
Subacute visual loss
The classic presentation of LHON is subacute, evolving
painless visual loss in young adults with male predomi-
nance (4:1) [43]. Majority of the cases have the con-
tralateral eye affected within a year and visual loss is often
irreversible. Although there is a conventional belief that
LHON mutations only affect eyes, other neurological fea-
tures such as dystonia [48], myoclonus [41], sensori-neural
deafness [66] may occur which broaden the spectrum of the
clinical phenotype in these mutations [48]. It is clear that
therefore LHON should be considered as a differential
diagnosis to the ‘atypical’ optical neuritis that shows no
recovery and Susac’s syndrome [97]. A link between
LHON mutations and multiple sclerosis was speculated for
a long time and a recent study has suggested that such
association may occur by chance even though mechanistic
interaction is possible [57].
Dominant optic neuropathy is caused by mutations in
the nuclear gene such as OPA1 and the irreversible visual
loss often occurs in the childhood [95] although late-onset
optic neuropathy after 4th decade [2] and adult-onset
CPEO and parkinsonism with subclinical optic neuropathy
have recently been described [12].
Chronic neurological presentations
Chronic progressive external ophthalmoplegia
and ptosis
More than half of adult patients have external ophthalmo-
plegia and/or ptosis in our large cohort of patients (un-
published). Ptosis and ophthamoplegia can be
asymmetrical at the outset but most cases become sym-
metrical with time. CPEO is one of the main presenting
features in adult patients with mitochondrial disease [77]
and ptosis often imposes more functional limitation than
the restricted eye movement because the extra-ocular
paresis occurs insidiously allowing cerebral adaptation and
symptomatic diplopia is less common. Some patients with
CPEO phenotype are occasionally misdiagnosed as other
conditions such as seronegative myasthenia gravis.
Myopathy
Many adult patients experience fatigue, exercise intoler-
ance and muscle weakness. The degree of proximal
myopathy is often mild on clinical testing and it progresses
slowly. Early loss of ambulation due to muscle weakness is
not a typical feature of adult mitochondrial disease with a
few exceptions such as patients with Kearns–Sayre syn-
drome caused by single deletion in mtDNA and TK2
mutation [4]. There is a risk of aspiration when facial and
oropharyngeal weakness is present in addition to the res-
piratory muscle weakness. Some patients may have normal
muscle strength and EMG study but complain of limited
exercise capacity with recurrent nausea and/or vomiting on
exertion due to lactic acidosis.
Ataxia
Cerebellar ataxia is often subtle at the onset and typically
progress with time and becomes debilitating in many
genotypes. Cerebellar atrophy is a common imaging find-
ing. Sensory ataxia due to dorsal root ganglionopathy is
one of the defining features in SANDO phenotype (sensory
ataxia, neuropathy, dysarthria and ophthalmoplegia) caused
by POLG mutations [42].
Neuropathy
Diminished or absent long tendon reflexes are a common
clinical finding and axonal neuropathy is the most common
finding in nerve conduction studies in adult patients with
mitochondrial disease with a few exceptions such as
demyelinating neuropathy described in patients with MNGIE
[25].A recent study showed that neuropathy is a useful feature
toguidemolecular diagnosis in adult patientswithCPEO[32].
Diagnostic approach
Comprehensive diagnostic criteria and guidelines have
been published to provide a framework for clinicians when
investigating patients with suspected mitochondrial disease
[8, 85, 86]. Patients who present with classic syndromes
such as MELAS, MERRF, LHON and Alpers disease can
be diagnosed by direct sequencing of mitochondrial genes
or POLG gene in blood. It is important to consider that
blood heteroplasmy (leucocytes) declines with age in
m.3243A[G [65] and ‘false negative result’ is possible in
older adults therefore concomitant testing of additional
tissue such as urinary epithelium is recommended. Some
nuclear gene mutations have been found to have associa-
tion with distinctive radiological appearances which can
expedite the candidate gene sequencing, these include
leukoencephalopathy with brainstem and spinal cord
involvement and lactate elevation (LBSL) caused by
DARS2 mutations [89] and leukoencephalopathy with
thalamus and brainstem involvement and high lactate
(LTBL) caused by EARS2 mutations [78].
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However, many mitochondrial diseases do not have
pathognomonic features that point towards a particular
genetic diagnosis and muscle biopsy remains important in
current clinical practice. The findings of muscle biopsy that
are supportive of mitochondrial disease include: ragged red
fibres (RRF), COX-negative fibres, individual complex or
multiple respiratory chain deficiency, qualitative (multiple
deletions) and quantitative (depletion) abnormalities in
mtDNA.
Next generation sequencing is a new and high-
throughput technique that allows sequencing of multiple
candidate genes simultaneously leading to a more rapid
diagnosis and increase the diagnostic yield [88] especially
in the well-phenotyped cohort of patients [84]. Clinical
exome sequencing is likely to become part of standard
clinical care for undiagnosed patients.
Treatment and long term management
Specific treatment in mitochondrial disease
Currently, there remains no effective and specific treatment
for vast majority of patients with mitochondrial disease.
Various treatments (mostly nutritional supplements) such
as co-enzyme Q10, carnitine, creatine, dichloroacetate and
vitamin ‘cocktails’ have been widely used based upon
anecdotal data and individual case reports, however,
Cochrane systemic review of treatments that were tested in
randomised-control trials concluded that none of these
treatment showed meaningful clinical efficacy [59]. Since
then, another randomised, controlled trial using idebenone
in LHON mutations found no significant result in the pri-
mary end point defined as the best recovery in visual acuity
but post hoc interaction analysis suggested benefits in those
with discordant visual acuities [38]. EPI-743, a novel anti-
oxidant has been reported to show clinical improvement in
small number of patients with Leigh syndrome [47] and
LHON [67] in the open-label clinical trials and phase 2B
randomized-control trial is currently in progress.
Although there is no formal clinical trial, supplement of
high dose co-enzyme Q10 (up to 2400 mg in three divided
doses in adults; 30 mg/kg in paediatric cases) in primary
co-enzyme Q10 biosynthetic defect has been reported to
show variable clinical improvement across different phe-
notypes [23].
L-arginine has been reported to be effective in treating
acute stroke-like episodes associated with m.3243A[G
mutation [39]. However, this result is yet to be replicated
by other research groups.
Allogenic haematopoietic stem cell transplant has
emerged as a promising therapeutics to restore the enzy-
matic function in patients with MNGIE caused by TYMP
mutations but this treatment is associated with high mor-
bidity and mortality [25, 75].
Supportive treatment and surveillance
for complications
Symptomatic treatment and screening for associated com-
plications remain fundamental to the management of
mitochondrial disease.
Acute seizure and stroke-like episodes
Early recognition and prompt, aggressive seizure man-
agement are crucial to mitigate the cellular metabolic crisis
perpetuated by the ictal activities [10]. The seizure man-
agement should follow the guidelines on status epilepticus
except sodium valproate is absolutely contra-indicated in
POLG mutations. Phenytoin was implicated in causing
paralytic ileus in a patient with stroke-like episodes [17],
however, this is likely to be a co-incidental finding as
pseudo-obstruction is a common complication associated
with MELAS syndrome [74] and we use this drug regularly
to control seizures. Anecdotal evidence on the use of
magnesium infusion [91], ketamine [64], ketogenic diet
[34, 46, 79], folinic acid supplement [30] in termination of
status epilepticus associated with POLG and m.3243A[G
has been reported.
Pseudo-obstruction
Several genetic mutations (TYMP, m.3243A[G and
POLG) have been associated with intestinal pseudo-ob-
struction [9, 63, 83, 90] involving small and/or large
intestine. Distinguishing this from mechanical obstruction
is of paramount importance as they tend to resolve with
conservative management alone and surgery has little role
and could exacerbate the metabolic crisis. Serum lactate is
not a reliable marker for tissue ischaemia in patients with
mitochondrial disease because some patients have persis-
tently raised lactate even when they are well. Aggressive
medical management of acute episodes is important as is
prevention by using regular laxatives.
Cardiac involvement
Cardiac involvement is often part of the multi-system
manifestation in adult mitochondrial DNA disease [7]
although isolated cardiomyopathy has been reported in rare
mtDNA mutations [26]. Cohort studies have shown that
hypertrophic cardiomyopathy and pre-excitation syndrome
are prevalent in m.3243A[G [37, 45] and m.8344A[G [13,
44] mutations, whereas conduction defect necessitating
pacemaker is associated with single, large scale deletion
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particularly among those who have Kearns-Sayre syn-
drome. Currently, there is limited longitudinal data study-
ing the prevalence of cardiac involvement in various
nuclear genes in adults [60]. Baseline cardiac assessment
with electrocardiogram (ECG) and echocardiogram should
be performed in all patients and cardiac magnetic reso-
nance in selected cases. Subsequent cardiac surveillance
should be tailored according to the initial findings but the
recommended interval is every 12 to 24 months [22, 55].
Diabetes mellitus
Diabetes mellitus is common in patients with m.3243A[G
and single, large scale mtDNA deletions [70]. Metformin is
best avoided because of the theoretical risk of lactic aci-
dosis. Treatment of mitochondrial diabetes is otherwise
similar to the usual form of diabetes although it appears
that it is associated with a more rapid progression to insulin
therapy [93].
Ptosis
A proportion of patients with CPEO develop significant
ptosis that obscures visual field. Corrective ptosis surgery
such as frontalis sling operation improves the functional
and cosmetic outcome in selected patients [3].
Deafness
Young onset, bilateral sensori-neural deafness is prevalent
in mitochondrial disease. The quality of life of many
patients can simply be improved with digital hearing aid
and cochlear implant can be reserved for those with severe
hearing loss [36, 81].
Genetic counselling and reproductive options
Similarly to other genetic disorders, screening for family
members at risk and offering genetic counselling is
essential in mitochondrial disease. For patients with
nuclear gene disorders, genetic counselling and reproduc-
tive options are identical to other nuclear defects. For
women with mtDNA mutations genetic counselling is a
challenging area. Patients should be reassured if they har-
bour sporadic mutation, such as single, large scale mtDNA
deletion, because risks of transmission are low. For
mtDNA point mutations, accurate elucidation of the risk of
transmission and prediction of disease status is extremely
challenging due to the genetic bottleneck effect and uneven
tissue segregation associated with some point mutations. It
is estimated that there are approximately 152 births per
year in the UK of children who carry potentially
pathogenic mitochondrial DNA mutations [27]. In view of
the complexity of mtDNA genetics, referral of child-
bearing age female patients to specialist centres for dis-
cussion of reproductive options is recommended. The
available options are chorionic villous sampling (CVS),
amniocentesis [52] and preimplantation genetic diagnosis
(PGD) [68, 87]. CVS and amniocentensis are performed at
different stages of pregnancy, 10–12 and 14–20 weeks,
respectively. PGD is an IVF procedure that involves
embryo biopsy and the selection of embryos with the
lowest mutation load. However, PGD will not benefit
carriers with homoplasmic mtDNA mutation.
Mitochondrial donation, either pronuclear transfer [18]
or metaphase II spindle transfer [82], is emerging as a
potential reproductive option to prevent the transmission of
mtDNA mutations. In the UK after many years of debate
and scientific scrutiny, Mitochondrial Donation Regula-
tions, were passed by both Houses of Parliament, making
mitochondrial donation legal for the first time in the UK.
The Human Fertilisation and Embryology Authority will
now develop a licencing framework through which appli-
cations can be considered on a case by case basis.
Conclusions
Over recent years there have been important advances in
mitochondrial disease, particularly in terms of diagnosis
and reproductive options available. The role of the clini-
cian remains crucial since a high index of clinical suspicion
and prompt recognition of complications remain essential
to make an earlier diagnosis and instigate a better man-
agement. Currently, the management of mitochondrial
disease is largely supportive; however, with the improved
understanding of disease mechanisms, ongoing treatment
trials and discovery of new therapeutic agents should give
hope for patients with mitochondrial disease.
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